11/19/2021, 4:46 PM (Source: TeleTrader)
more TeleTrader news


Chart for: Pfizer Inc

EMA starts reviewing Pfizer's COVID-19 pill

The European Medicines Agency (EMA) announced on Friday it has started reviewing the use of Pfizer Inc.'s oral treatment against COVID-19, Paxlovid.

"EMA's human medicines committee (CHMP) will look at data from a study comparing the effect of Paxlovid with that of a dummy treatment (placebo) in non-hospitalized patients with mild to moderate COVID-19 who were at high risk of progressing to severe disease," the agency's statement read.

Pfizer previously announced Paxlovid decreases the potential of fatalities and hospitalizations linked to COVID-19 by 89%. Meanwhile, it applied for an emergency use authorization (EUA) of the treatment in the United States.

Baha Breaking News (BBN) / JR